Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2004 Oct;89(10):961–965. doi: 10.1136/adc.2003.046714

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease

A Duppenthaler 1, R Ammann 1, M Gorgievski-Hrisoh 1, J Pfammatter 1, C Aebi 1
PMCID: PMC1719693  PMID: 15383442

Abstract

Background: Haemodynamically significant congenital heart disease (CHD) is a risk factor for severe respiratory syncytial virus (RSV) disease in young children. Population based data on the incidence of RSV hospitalisations in CHD patients are needed to estimate the potential usefulness of RSV immunoprophylaxis using palivizumab.

Aims: (1) To obtain population based RSV hospitalisation rates in children <24 months of age with CHD. (2) To compare these rates with non-CHD patients and with previous studies. (3) To determine the number of patients needed to treat (NNT) with palivizumab to prevent one RSV hospitalisation.

Methods: Six year, longitudinal, population based study at an institution, which is the sole provider of primary to tertiary in-patient care for a precisely defined paediatric population.

Results: RSV hospitalisation rates (per 100 child-years) in CHD patients aged <6, <12, 12–24, and <24 months of age were 2.5 (95% CI 0.8 to 5.6), 2.0 (0.8 to 3.8), 0.5 (0.1 to 1.8), and 1.3 (0.6 to 2.3), respectively, and the relative risk (RR) in comparison with non-CHD patients was 1.4 (0.6 to 3.1), 1.6 (0.8 to 3.2), 2.7 (0.7 to 9.7), and 1.8 (1.0 to 3.3), respectively. NNT was between 80 (35 to 245) and 259 (72 to 2140) for various age groups.

Conclusion: RSV hospitalisation rates in CHD patients were fourfold lower than reported from the USA. Based on these low rates and RR, unrestricted use of palivizumab does not appear to be justified in this study area.

Full Text

The Full Text of this article is available as a PDF (94.7 KB).

Figure 1.

Figure 1

Open in a new tab

 Epidemiology of RSV hospitalisations in the Canton of Bern, Switzerland. (A) Frequency of RSV hospitalisations in each study year in children <24 months of age. (B) Distribution of risk factors among patients hospitalised for RSV infection in each study year. CHD, congenital heart disease; BPD, bronchopulmonary dysplasia.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyce T. G., Mellen B. G., Mitchel E. F., Jr, Wright P. F., Griffin M. R. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000 Dec;137(6):865–870. doi: 10.1067/mpd.2000.110531. [DOI] [PubMed] [Google Scholar]
  2. Brandenburg A. H., Jeannet P. Y., Steensel-Moll H. A., Ott A., Rothbarth P. H., Wunderli W., Suter S., Neijens H. J., Osterhaus A. D., Siegrist C. A. Local variability in respiratory syncytial virus disease severity. Arch Dis Child. 1997 Nov;77(5):410–414. doi: 10.1136/adc.77.5.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chan I. S., Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999 Dec;55(4):1202–1209. doi: 10.1111/j.0006-341x.1999.01202.x. [DOI] [PubMed] [Google Scholar]
  4. Cunningham C. K., McMillan J. A., Gross S. J. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics. 1991 Sep;88(3):527–532. [PubMed] [Google Scholar]
  5. Duppenthaler A., Gorgievski-Hrisoho M., Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly. 2001 Mar 24;131(11-12):146–151. doi: 10.4414/smw.2001.09681. [DOI] [PubMed] [Google Scholar]
  6. Duppenthaler A., Gorgievski-Hrisoho M., Frey U., Aebi C. Two-year periodicity of respiratory syncytial virus epidemics in Switzerland. Infection. 2003 Mar;31(2):75–80. doi: 10.1007/s15010-002-3124-8. [DOI] [PubMed] [Google Scholar]
  7. Eriksson M., Bennet R., Rotzén-Ostlund M., von Sydow M., Wirgart B. Zweygberg. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91(5):593–598. doi: 10.1080/080352502753711740. [DOI] [PubMed] [Google Scholar]
  8. Feltes Timothy F., Cabalka Allison K., Meissner H. Cody, Piazza Franco M., Carlin David A., Top Franklin H., Jr, Connor Edward M., Sondheimer Henry M., Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532–540. doi: 10.1067/s0022-3476(03)00454-2. [DOI] [PubMed] [Google Scholar]
  9. Fixler D. E. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol. 1996 May-Jun;17(3):163–168. doi: 10.1007/BF02505206. [DOI] [PubMed] [Google Scholar]
  10. Glezen W. P., Taber L. H., Frank A. L., Kasel J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986 Jun;140(6):543–546. doi: 10.1001/archpedi.1986.02140200053026. [DOI] [PubMed] [Google Scholar]
  11. Groothuis J. R., Simoes E. A., Levin M. J., Hall C. B., Long C. E., Rodriguez W. J., Arrobio J., Meissner H. C., Fulton D. R., Welliver R. C. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993 Nov 18;329(21):1524–1530. doi: 10.1056/NEJM199311183292102. [DOI] [PubMed] [Google Scholar]
  12. Hall C. B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001 Jun 21;344(25):1917–1928. doi: 10.1056/NEJM200106213442507. [DOI] [PubMed] [Google Scholar]
  13. Hall C. B., Stevens T. P., Swantz R. J., Sinkin R. A., McBride J. T. Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr Infect Dis J. 1999 Oct;18(10):850–853. doi: 10.1097/00006454-199910000-00003. [DOI] [PubMed] [Google Scholar]
  14. Hoffman J. I., Christianson R. Congenital heart disease in a cohort of 19,502 births with long-term follow-up. Am J Cardiol. 1978 Oct;42(4):641–647. doi: 10.1016/0002-9149(78)90635-5. [DOI] [PubMed] [Google Scholar]
  15. Jobe A. H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060. [DOI] [PubMed] [Google Scholar]
  16. Kamal-Bahl Sachin, Doshi Jalpa, Campbell James. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034–1041. doi: 10.1001/archpedi.156.10.1034. [DOI] [PubMed] [Google Scholar]
  17. Kristensen K., Dahm T., Frederiksen P. S., Ibsen J., Iyore E., Jensen A. M., Kjaer B. B., Olofsson K., Pedersen P., Poulsen S. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatr Infect Dis J. 1998 Nov;17(11):996–1000. doi: 10.1097/00006454-199811000-00006. [DOI] [PubMed] [Google Scholar]
  18. MacDonald N. E., Hall C. B., Suffin S. C., Alexson C., Harris P. J., Manning J. A. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982 Aug 12;307(7):397–400. doi: 10.1056/NEJM198208123070702. [DOI] [PubMed] [Google Scholar]
  19. Meissner H. Cody, Long Sarah S., American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003 Dec;112(6 Pt 1):1447–1452. doi: 10.1542/peds.112.6.1447. [DOI] [PubMed] [Google Scholar]
  20. Mitchell S. C., Korones S. B., Berendes H. W. Congenital heart disease in 56,109 births. Incidence and natural history. Circulation. 1971 Mar;43(3):323–332. doi: 10.1161/01.cir.43.3.323. [DOI] [PubMed] [Google Scholar]
  21. Parrott R. H., Kim H. W., Arrobio J. O., Hodes D. S., Murphy B. R., Brandt C. D., Camargo E., Chanock R. M. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973 Oct;98(4):289–300. doi: 10.1093/oxfordjournals.aje.a121558. [DOI] [PubMed] [Google Scholar]
  22. Simoes E. A., Sondheimer H. M., Top F. H., Jr, Meissner H. C., Welliver R. C., Kramer A. A., Groothuis J. R. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr. 1998 Oct;133(4):492–499. doi: 10.1016/s0022-3476(98)70056-3. [DOI] [PubMed] [Google Scholar]
  23. Tulloh Robert, Marsh Michael, Blackburn Michael, Casey Frank, Lenney Warren, Weller Peter, Keeton Barry R., Working Group of the British Paediatric Cardiac Association Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young. 2003 Oct;13(5):420–423. [PubMed] [Google Scholar]
  24. Weigl J. A., Puppe W., Schmitt H. J. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001 Jul;20(7):452–459. doi: 10.1007/s100960100527. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES